-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
February 25, the State Drug Administration Board conditionally approved the Kangxi Nuo biological stock company restructuring novel coronavirus vaccine (adenovirus type 5 vector) application for registration.
Management prevent infection COVID-19
CanSino's recombinant new coronavirus vaccine (type 5 adenovirus vector) (Ad5-nCoV, trade name is Keweisha?), has carried out global multi-center phase III clinical trials in 5 countries including Pakistan, Mexico, Russia, Chile and Argentina In the study, more than 40,000 subjects have been vaccinated and interim data analysis has been completed.
The results of the analysis of data during the phase III clinical trial of Ad5-nCoV showed that: 28 days after a single injection of vaccine, the overall protective effect of the vaccine on all symptoms was 65.
Ad5-nCoV protection effectiveness data results meet the relevant technical standards of the World Health Organization and the relevant standards in the "Guidelines for Clinical Evaluation of Novel Coronavirus Preventive Vaccines (Trial)" issued by the National Medical Products Administration ("National Medical Products Administration").
Leave a message here
